Freeman Esther E, White Richard G, Bakker Roel, Orroth Kate K, Weiss Helen A, Buvé Anne, Hayes Richard J, Glynn Judith R
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Vaccine. 2009 Feb 5;27(6):940-6. doi: 10.1016/j.vaccine.2008.11.074. Epub 2008 Dec 9.
Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.
2型单纯疱疹病毒（HSV2）感染会增加艾滋病毒的传播。我们使用基于个体的模型STDSIM，探讨了一种潜在的HSV2预防性疫苗对非洲艾滋病毒发病率的影响。一项在5年内实现70%覆盖率的疫苗接种活动，使用的疫苗可在10年内将HSV2感染易感性和HSV2再激活降低75%，20年后艾滋病毒发病率降低了30%-40%（范围为4%-66%）。在20年的时间里，在大多数情况下，避免一例艾滋病毒感染所需的疫苗接种次数不到100次。HSV2疫苗可能对艾滋病毒发病率产生重大影响。需要加大力度研发有效的HSV2疫苗。
Zotero 插件
